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Reply
We greatly appreciate the interest in our paper (1) and the astute
comments by Drs. Tsigkas, Xanthopoulou, and Alexopoulos who
highlight the use of embolic protection devices (EPDs) in saphe-
nous vein graft (SVG) percutaneous coronary interventions (PCI)
and the importance of the amount of myocardium in jeopardy.
While we agree that the amount of jeopardized myocardium is an
important predictor of outcome, the information necessary to
calculate the amount of myocardium in jeopardy during PCI is not
available in the CathPCI Registry. EPDs were used in 19.64% of
SVG PCIs during the study period. EPD use was not associated
with in-hospital mortality in univariable analysis (odds ratio:
0.988, 95% confidence interval: 0.870 to 1.122) or multivariable
analysis (odds ratio: 0.935, 95% confidence interval: 0.813 to
1.075). Longer-term follow-up is likely needed to detect an impact
from EPD use on clinical outcomes.
EPDs have been proved to reduce the incidence of post-SVG
PCI myocardial infarction, and have a Class I indication in the
American College of Cardiology/American Heart Association
PCI guidelines. Yet, EPDs remain underutilized both in the
United States and in Europe (2), due to device complexity,
difficulties assessing the embolization risk of each SVG lesion,
unavailability of a universally applicable EPD, and lack of reim-
bursement (3,4).
The similarity of the findings from the population of Xantho-
poulou et al. (5) and from NCDR (1) strengthen the conclusionthat native coronary artery PCI is preferable to SVG PCI in prior
coronary artery bypass graft patients, if technically feasible. Given
the rapid advances in complex PCI techniques, especially chronic
total occlusion PCI (6,7), native coronary artery interventions are
likely to be increasingly utilized in the future in patients presenting
with SVG failure.
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